Wednesday, March 13, 2013
inVentiv Health, a global provider of clinical, commercial and consulting services, announced that its existing CRO, PharmaNet/i3, will be renamed inVentiv Health Clinical. This renaming reflects the closer alignment between the clinical segment and inVentiv’s commercial and consulting services.
PharmaNet/i3, inVentiv Health’s clinical segment and a provider of clinical development services, has appointed Dr. Susan C. Stansfield as executive vice president of clinical operations for phase II-IV development in Europe, Middle East and Africa (EMEA), Asia-Pacific and Latin America.
PharmaNet/i3, inVentiv Health’s clinical segment, has appointed Robert Lasser, M.D., MBA, vice president and general manager, neuroscience, overseeing the management of all clinical projects handled by PharmaNet/i3’s neuroscience group and the Rater Training Services team. Dr. Lasser will be based in Princeton, N.J.